Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Breast Neoplasms 33Neoplasms 31Melanoma 24Neoplasm Metastasis 22Leukemia, Myeloid, Acute 21Colorectal Neoplasms 18Prostatic Neoplasms 17Multiple Myeloma 17Lung Neoplasms 17Ovarian Neoplasms 14Myelodysplastic Syndromes 13Squamous Cell Carcinoma of Head and Neck 12Recurrence 12Lymphoma, Non-Hodgkin 12Carcinoma, Renal Cell 11Uterine Cervical Neoplasms 10Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Glioblastoma 10Brain Neoplasms 10Carcinoma, Hepatocellular 9Stomach Neoplasms 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Lymphoma 7Hodgkin Disease 7Head and Neck Neoplasms 7Glioma 7

Interventions

tislelizumab 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Extensive Stage Small Cell Lung Cancer × 90 days × Clear all
NCT06897579 2026-04-28

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
40 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡